Table 1.

Characteristics of Trials Included in the Meta‐Analysis

Author, Year	Follow‐up (Months)	Intervention Group	Control Group	Clinical Characteristics	Ejection Fraction	Patients Treatment/Control (% Women)	Mean Age, Years (SD)
Sato 200220	15 months	Spironolactone 25 mg/day+ACE inhibitor	ACE inhibitor only	Essential Hypertension, LVH	>50%	10/10 (45%)	53
Grandi 200224	6 months	Canerenone 50 mg/day+ACE inhibitor	ACE inhibitor only	Essential HTN, LVH and LVDD	Normal	17/17 (38%)	56
Roonsitrong 200521	4 months	Spironolactone 25 mg/day	Placebo	Mild diastolic dysfunction	>50%	15/15 (78%)	71
Kosmala 201122	6 months	Spironolactone 25 mg/day	Placebo	Metabolic syndrome	>50%	40/39 (54%)	59
Kosmala 201323	6 months	Spironolactone 25 mg/day	Placebo	BMI >30+diastolic dysfunction	>50%	58/55 (62%)	58
Mottram 200426	6 months	Spironolactone 25 mg/day	Placebo	Hypertension, diastolic heart failure (NYHA class II)	>50%	15/15 (63%)	62
Liu 200629	6 months	Spironolactone Mean dose: 47 mg/day	Usual care	Diastolic heart failure (NYHA class II/III)	>50%	40/38 (80%)	NA
Mak 200927	12 months	Eplerenone 25 to 50 mg/daily	Usual care	HFPEF+evidence of diastolic dysfunction	>45%	24/20 (54%)	80
Deswal 201125	6 months	Eplerenone 25 to 50 mg/daily	Placebo	HFPEF (NYHA class II/III)	>50%	21/23 (7%)	70
Edlemann 201328	12 months	Spironolactone 25 mg/day	Placebo	HFPEF (NYHA class II/III)	>50%	213/209 (52%)	67
Kurrelmeyer 201430	6 months	Spironolactone 25 mg/day	Placebo	HFPEF (NYHA class II/III)	>50%	24/24 (100%)	71

ACE indicates angiotensin‐converting enzyme; BMI, body mass index; HFPEF, heart failure with preserved ejection fraction; HTN, hypertension; LVDD, left ventricular diastolic dysfunction; LVH, left ventricular hypertrophy; NA, not available; NYHA, New York Heart Association.